Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
An Bras Dermatol ; 97(4): 501-504, 2022.
Article in English | MEDLINE | ID: covidwho-1881588

ABSTRACT

COVID-19 disease caused by the SARS-CoV-2 coronavirus causes a wide range of clinical manifestations, ranging from mild to severe, with the main ones affecting the respiratory tract, such as pneumonia. In patients with greater severity, the high frequency of bacterial and fungal coinfection stands out, a situation related both to the patient's pre-existing comorbidities and due to the hospitalization itself. Cases of mucormycosis associated with COVID-19 were highlighted in the lay and scientific media, with the increase in mycosis cases being directly and indirectly attributed to the viral infection. This report describes a case of rhino-orbito-cerebral mucormycosis in a diabetic patient hospitalized for COVID-19, whose diagnosis was confirmed by identifying the agent Rhizopus microsporus var. microsporus through culture for fungi and PCR examination.


Subject(s)
COVID-19 , Diabetes Mellitus , Mucormycosis , Antifungal Agents/therapeutic use , COVID-19/complications , Diabetes Mellitus/drug therapy , Humans , Mucormycosis/diagnosis , Rhizopus , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL